[Dyslipidemia and abdominal obesity: therapeutic approaches (Part II)].
Lifestyle changes form the basis of the therapeutic management of dyslipidemia associated with abdominal obesity and other risk factors associated with an excess of visceral adipose tissue. The use of lipid-lowering agents is justified if the therapeutic objectives are not attained by lifestyle changes alone. New therapeutic approaches are aimed directly at the excess visceral adipose tissue, and the CB1 receptor blockers are particularly promising for improving the overall lipid profile for patients with abdominal obesity.
Farnier
M
M
Point Médical, dijon. michelfarnier@nerim.net
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D004032:Diet; D050171:Dyslipidemias / Q000150:complications / Q000628:therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008019:Life Style; D009765:Obesity / Q000150:complications / Q000517:prevention & control*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors
D019440:Anti-Obesity Agents; D000960:Hypolipidemic Agents; D043884:Receptor, Cannabinoid, CB1